The paper addresses only early preliminary work and says nothing...

The paper addresses only early preliminary work and says nothing about the current two large FDA phase III's that are being conducted world-wide. These late-stage trials , although lengthy, will show final proof of the worth of aducanumab. Prana has never progressed beyond mid-stage trials and is awaiting approval to enter their very first FDA Phase III in its history. This will be for HD, not for AD, following removal of the FDA's HD partial clinical hold. Pierre and itm's abstract also does not address aducanumab's admission to the EMA's PRIME program.

This is the true story of only one investigative drug that is steadily moving along according to regulatory protocol. There are also other prospects working to find results for AD. It's futile to concentrate only on Prana Biotech and Biogen.